414 related articles for article (PubMed ID: 30642538)
21. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
22. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells.
Rizza P; Santini SM; Logozzi MA; Lapenta C; Sestili P; Gherardi G; Lande R; Spada M; Parlato S; Belardelli F; Fais S
J Virol; 1996 Nov; 70(11):7958-64. PubMed ID: 8892919
[TBL] [Abstract][Full Text] [Related]
23. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection.
Briscoe DM; Dharnidharka VR; Isaacs C; Downing G; Prosky S; Shaw P; Parenteau NL; Hardin-Young J
Transplantation; 1999 Jun; 67(12):1590-9. PubMed ID: 10401767
[TBL] [Abstract][Full Text] [Related]
24. HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy.
Satheesan S; Li H; Burnett JC; Takahashi M; Li S; Wu SX; Synold TW; Rossi JJ; Zhou J
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343582
[TBL] [Abstract][Full Text] [Related]
25. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection.
Shiroki R; Poindexter NJ; Woodle ES; Hussain MS; Mohanakumar T; Scharp DW
Transplantation; 1994 Jun; 57(11):1555-62. PubMed ID: 8009588
[TBL] [Abstract][Full Text] [Related]
26. NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo.
Spranger S; Frankenberger B; Schendel DJ
J Transl Med; 2012 Feb; 10():30. PubMed ID: 22364226
[TBL] [Abstract][Full Text] [Related]
27. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
28. Enhanced development of functional human NK cells in NOD-scid-IL2rg
Aryee KE; Burzenski LM; Yao LC; Keck JG; Greiner DL; Shultz LD; Brehm MA
FASEB J; 2022 Sep; 36(9):e22476. PubMed ID: 35959876
[TBL] [Abstract][Full Text] [Related]
29. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
[TBL] [Abstract][Full Text] [Related]
30. Novel immunological approach to asses donor reactivity of transplant recipients using a humanized mouse model.
Fukasaku Y; Goto R; Ganchiku Y; Emoto S; Zaitsu M; Watanabe M; Kawamura N; Fukai M; Shimamura T; Taketomi A
Hum Immunol; 2020 Jul; 81(7):342-353. PubMed ID: 32345498
[TBL] [Abstract][Full Text] [Related]
31. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
[TBL] [Abstract][Full Text] [Related]
32. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
Zhao Y; Shuen TWH; Toh TB; Chan XY; Liu M; Tan SY; Fan Y; Yang H; Lyer SG; Bonney GK; Loh E; Chang KTE; Tan TC; Zhai W; Chan JKY; Chow EK; Chee CE; Lee GH; Dan YY; Chow PK; Toh HC; Lim SG; Chen Q
Gut; 2018 Oct; 67(10):1845-1854. PubMed ID: 29602780
[TBL] [Abstract][Full Text] [Related]
33. Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice.
Turgeon NA; Banuelos SJ; Shultz LD; Lyons BL; Iwakoshi N; Greiner DL; Mordes JP; Rossini AA; Appel MC
Exp Biol Med (Maywood); 2003 Oct; 228(9):1096-104. PubMed ID: 14530522
[TBL] [Abstract][Full Text] [Related]
34. The Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rγ null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for Treatment With Adalimumab.
Jodeleit H; Caesar J; Villarroel Aguilera C; Sterz S; Holdt L; Beigel F; Stallhofer J; Breiteneicher S; Bartnik E; Siebeck M; Gropp R
Inflamm Bowel Dis; 2020 Mar; 26(4):557-569. PubMed ID: 31782956
[TBL] [Abstract][Full Text] [Related]
35. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
Nonoyama S; Smith FO; Ochs HD
J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
[TBL] [Abstract][Full Text] [Related]
36. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.
Alcantar-Orozco EM; Gornall H; Baldan V; Hawkins RE; Gilham DE
Hum Gene Ther Methods; 2013 Oct; 24(5):310-20. PubMed ID: 23931270
[TBL] [Abstract][Full Text] [Related]
37. An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer.
Shang P; Yu L; Cao S; Guo C; Zhang W
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1497-1506. PubMed ID: 36269133
[TBL] [Abstract][Full Text] [Related]
38. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract][Full Text] [Related]
39. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
